Related Experiment Videos
Therapeutic and collateral effects of 25-hydroxycholecalciferol in vitamin D deficiency
Insights
This study compared 25-hydroxycholecalciferol (25-HCC) and vitamin D3 for treating nutritional rickets in infants. Both treatments were effective, showing no significant therapeutic advantage of 25-HCC over vitamin D3.
Area of Science:
- Pediatrics
- Endocrinology
- Nutritional Science
Background:
- Nutritional rickets is a significant concern in infants.
- Vitamin D deficiency is a primary cause of rickets.
- Assessing alternative treatment options is crucial for pediatric care.
Purpose of the Study:
- To compare the efficacy of 25-hydroxycholecalciferol (25-HCC) and vitamin D3 in treating nutritional rickets in infants.
- To evaluate the clinical and biochemical responses to these treatments.
- To assess the safety and effectiveness of 25-HCC in a pediatric population.
Main Methods:
- A randomized controlled trial involving infants aged 3-18 months with nutritional rickets.
- Group I received 25-hydroxycholecalciferol (25-HCC), Group II received vitamin D3.
- A control group (Group III) received a lower dose of 25-HCC.
Main Results:
- Both 25-HCC and vitamin D3 improved biochemical parameters in rachitic infants.
- Plasma alkaline phosphatase remained elevated post-treatment in both treatment groups.
- The control group showed increased plasma and urine calcium levels with low-dose 25-HCC.
Conclusions:
- 25-hydroxycholecalciferol (25-HCC) is as effective as vitamin D3 in treating nutritional rickets in infants.
- No significant therapeutic advantage of 25-HCC over vitamin D3 was demonstrated.
- Further research may explore optimal dosing and long-term effects.
Abstract:
The clinical and biochemical response to 25-hydroxycholecalciferol (25-HCC) and vitamin D3, 150 microgram/day for 20 days has been compared in infants aged 3--18 months with nutritional rickets. The infants were allocated at random to Group I (11 infants) treated with 25HCC and Group II (9 infants) treated with vitamin D3. In addition 15 matched control children without rickets were allocated to Group III and received 25-HCC 75 microgram/day for 20 days. Preliminary studies showed that plasma calcium, phosphorus, alkaline phosphatase and urine pH all differed significantly between the rachitic and control groups. The biochemical parameters in both groups of rachitic children became normal after treatment with the exception of plasma alkaline phosphatase which remained elevated. The control group showed a significant increase in plasma and urine calcium values in spite of the low dose of 25-HCC. The findings suggest that 25-HCC is as effective as vitamin D3 in the treatment of rickets but did not demonstrate any therapeutic advantage.